Stockwinners Market Radar for November 13, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:45 EST HP Inc. raises quarterly dividend to 17.6c from 16.0c per share - The dividend is payable on January 2, 2020, to stockholders of record as of the close of business on December 11, 2019.

18:46 EST Hersha Hospitality CEO: Airnb has definitely had an impact - In an interview on CNBC's Mad Money, Hersha Hospitality CEO Jay Shah said: It's a bit of a risk-off environment with hotel stocks right now... There is flatter growth in New York.

18:33 EST ProPetro discloses U.S. SEC probe - ProPetro has filed a Current Report on Form 8-K that provides updates regarding the audit committee's internal review, as well as related accounting conclusions regarding the existence of at least two material weaknesses, recently filed shareholder litigation, a Securities and Exchange Commission investigation and related matters. The audit committee has continued to review the matters previously disclosed in the company's Current Reports on Form 8-K filed with the SEC on August 8, 2019 and October 9, 2019. Since October 9, 2019, the Audit Committee has identified one related party transaction that was not previously disclosed and is described in greater detail in the Form 8-K. The company and certain of its officers and directors have been named in a shareholder class action lawsuit that was filed in September 2019 and remains in its early stages. The company has also been advised by the SEC that the SEC has opened an investigation into the company, and the company has cooperated and expects to continue to cooperate with the SEC's investigation. The company cannot currently predict the duration, scope or results of either of these proceedings, including whether either or both may have a material adverse impact on the company. ProPetro has also filed a Form 12b-25, Notification of Late Filing, with the SEC today regarding its inability to timely file its Form 10-Q for the third quarter of 2019. The company does not currently expect to be in a position to file amended, delinquent or future SEC filings prior to the end of 2019. As described in the Form 8-K and Form 12b-25, the company will continue to seek to take all appropriate actions and make necessary filings with the SEC with a view to becoming current in its filing obligations under the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable.

18:19 EST Equus reports Q3 NAV per share of $3.63 - Equus Total Return reports net assets as of September 30, 2019, of $49.0 million, an increase of approximately $1.1 million since June 30, 2019. Net asset value per share increased to $3.63 as of September 30, 2019 from $3.55 as of June 30, 2019.

17:57 EST Copa Holdings reports October capacity down 4.8%, traffic down 1.4% - Copa Holdings released preliminary passenger traffic statistics for October, 2019. Copa Holdings' capacity, or ASMs, decreased 4.8%, while system-wide passenger traffic, or RPMs, decreased only 1.4% year over year. As a result, system load factor for the month was 84.9%, 2.9 percentage points higher than October 2018.

17:44 EST BAE Systems awarded maximum $270.6M Navy contract modification - BAE Systems was awarded a maximum-value $270.6M, firm-fixed-price modification to its previously-awarded contract to exercise option year three for the accomplishment of fixed-priced delivery orders for emergent and continuous ship maintenance availabilities for ships homeported in Mayport, Florida. These six companies will have the opportunity to provide offers for individual delivery orders. Work will be performed in Mayport, Florida, and is expected to be completed by November 2020. No funding will be obligated at time of award. The Southeast Regional Maintenance Center is the contracting activity.

17:32 EST Suncor increases share repurchase program by $500M - Suncor's board approved an increase to the company's current share repurchase program of an additional $500M increasing the program to $2.5B from $2.0B. Should market conditions allow, Suncor expects to repurchase between $2.0B-$2.5B of common shares by the end of February 2020. As of November 8, 2019, Suncor has completed repurchases of $1.74B, or approximately 42.7M shares under the board approved program, representing approximately 2.8% of total shares outstanding. Since recommencing the share repurchase program in May of 2017, Suncor has repurchased approximately $6.6B, or 149.3M shares, for approximately 8.9% of total shares outstanding at that time.

17:07 EST Domino's Pizza's Goldman sells 2,486 common shares - In a regulatory filing, Domino's Pizza director James A. Goldman disclosed the sale of 2,486 common shares of the company at a price of $279.978 per share on November 11.

16:54 EST Cisco says cyber security is a top priority for customers - Says innovation pipeline remains strong. Says remains in a challenging macro-environment. Says all business were up in Q1 besides routing. Sees Q2 tax rate of 20%. Says quarter had tough comparisons. Says feeling positive impact of software mix on margins. Sees pricing erosion for service market now that DRAM prices are going down. Comments taken from Q1 earnings conference call.

16:52 EST RLI Corp. declares special cash dividend of $1.00 per share - Payable on December 20 to shareholders of record as of November 29.

16:48 EST Interpace Diagnostics changes name to Interpace Biosciences - Interpace Diagnostics (IDXG) has changed its name to Interpace Biosciences to better reflect its new business model that combines its traditional esoteric molecular diagnostic business with its recent acquisition of the BioPharma business of Cancer Genetics (CGIX), now known as Interpace Pharma Solutions, that uses its proprietary test systems and platforms to support drug discovery and development valued by pharmaceutical and biotechnology companies. Interpace Biosciences will continue to trade on NASDAQ as IDXG.

16:42 EST BHP Group names Mike Henry CEO - The board of BHP Group announced that Mike Henry has been appointed Chief Executive Officer of BHP, following a thorough succession process. Henry will assume the role of CEO and Executive Director effective 1 January 2020, replacing Andrew Mackenzie who will retire as CEO on 31 December 2019. Mike Henry's employment contract will be effective from 1 January 2020. He was appointed to his current role of President Operations Minerals Australia in 2016, and has been a member of the Executive Leadership Team since 2011.

16:38 EST Cango receives NYSE letter of listing standards non-compliance - Cango received a notification letter from the NYSE indicating that the company is not currently in compliance with NYSE listing standards for stockholders, including number of total stockholders of at least 400 or number of total stockholders of at least 1,200, if the average monthly volume is less than 100,000 for the most recent 12 months. Therefore, the company is now subject to the procedures set forth in Sections 801 and 802 of the Manual. The company needs to respond within 90 days, which is no later than January 22, 2020, with a business plan that demonstrates how the company expects to return to compliance with the first two standards within a maximum period of 18 months from receipt of the Notification Letter. The Notification has no impact on listing or trading, as Cango's ADS will continue to be listed and traded on the NYSE.

16:33 EST American Outdoor Brands: CFO Buchanan to retire after completion of spin-off - James Debney, President and CEO, and Jeffrey Buchanan, CFO, will continue to lead AOBC until the completion of the separation and spin-off of the outdoor products and accessories business in the second half of calendar 2020. Buchanan will serve as the lead executive on coordinating and executing the separation of the two businesses. Upon the successful completion of the spin-off, Buchanan plans to retire after 15 years of service to AOBC, including six years as a member of the Board of Directors prior to becoming CFO. Upon Buchanan's retirement, Deana McPherson will assume the role of CFO of Smith & Wesson Brands, and H. Andrew Fulmer will serve as CFO of American Outdoor Brands.

16:32 EST Zosano Pharma announces completion of pre-NDA meetings with FDA for Qtrypta - Zosano Pharma announced that it has received minutes from pre- New Drug Application meetings with the FDA for the acute treatment of migraine for Qtrypta. The purpose of the meetings was to confirm the completion of all requisite studies, as well as the proposed clinical, non-clinical, and chemistry, manufacturing, and controls content and format of the company's NDA submission, which the company expects to make in December 2019. The company was granted two separate pre-NDA meetings to discuss the development program. A face to face meeting was held with the FDA in September to discuss the nonclinical and clinical portions of the program. A second pre-NDA meeting request was granted to discuss CMC, and FDA recently provided its written responses to the company's questions in lieu of holding an in-person meeting. Based on the feedback from the FDA, the company believes the information included in its planned NDA will be sufficient for the FDA to file the NDA for substantive review. "We are encouraged by the pre-NDA minutes received from FDA after our collaborative meetings. This is an important milestone as we head into the final stages of completion of the NDA," said Hayley Lewis, Senior Vice President, Operations.

16:26 EST American Outdoor Brands split targeted for completion in 2H20 - The transaction is currently targeted to be completed in the second half of calendar 2020, subject to final approval by AOBC's Board of Directors, customary regulatory approvals, and tax and legal considerations. Throughout the separation process, AOBC management will remain committed to the business and all key stakeholders, including customers, employees, and stockholders. AOBC plans to announce further details on the composition of the respective Boards of Directors ahead of the completion of the transaction. Investor roadshows will be scheduled for both companies during the first half of calendar 2020.

16:22 EST American Outdoor Brands to separate into two publicly traded companies - American Outdoor Brands announced that its Board of Directors has unanimously approved proceeding with a plan to spin-off its outdoor products and accessories business as a tax-free stock dividend to its stockholders. The proposed transaction, which is expected to be completed in the second half of calendar 2020, would create two independent publicly traded companies: Smith & Wesson Brands (which would encompass the firearm business) and American Outdoor Brands (which would encompass the outdoor products and accessories business). The purpose of the spin-off is to enable the management team of each company to focus on its specific strategies, including (1) structuring its business to take advantage of growth opportunities in its specific markets; (2) tailoring its business operation and financial model to its specific long-term strategies; and, (3) aligning its external financial resources, such as stock, access to markets, credit, and insurance factors, with its particular type of business. Barry Monheit, Chairman of the Board, said, "There have been significant changes in the political climate as well as the economic, investing, and insurance markets since we embarked upon what we believe have been our very successful diversification efforts. We believe that separating into two independent public companies will allow each company to better align its strategic objectives with its capital allocation priorities. We also believe that this action will give the investment community clearer insight into the value creation potential in each of these independent companies, ultimately driving enhanced stockholder value. From the standpoint of our stockholders, at the time of the spin-off, the AOBC stockholders will own 100% of each company, thereby maintaining their pre-spin interest in both companies, and will thereafter have the ability to make distinct investment decisions tailored to their particular investment profile." James Debney will become CEO of American Outdoor Brands, Inc. upon successful completion of the spin-off of that company. Debney joined Smith & Wesson in November 2009 as President of the Firearms Division, and, in 2011, was promoted to President, CEO, and Board Member of its parent company, AOBC. Under Debney's leadership, AOBC grew its market-leading firearm business, while developing and successfully executing a diversification strategy to expand into the outdoor products and accessories business. Debney oversaw the acquisition of a number of well-known consumer brands that, when combined with organic growth, helped the new division to deliver 25% of AOBC's total fiscal 2019 revenue. Debney has over 25 years of leadership and management experience in multi-factory, multinational organizations that address both consumer and business-to-business environments. He previously served as President of Presto Products Company, a $500 million former plastic products business unit of Alcoa Consumer Products.

16:20 EST Navistar reports impact of UAW'S strike at General Motors of $140M - Navistar (NAV) reports that the six-week strike of the United Auto Workers union at General Motors (GM) impacted the company's ability to deliver approximately 5,000 vehicles to customers during the company's Q4. Due to Navistar's lost production, the company's 2019 revenue and adjusted EBITDA is expected to be impacted by approximately $140M and $15M, respectively."We are pleased that we have resumed production at our Springfield, Ohio truck assembly plant last week," said CFO Walter G. Borst. "However, the shutdown of our Springfield plant affected our workforce and the delivery of certain units to customers. As a result, our 2019 full year revenue and adjusted EBITDA is now expected to be at the low end of our guidance range." Navistar halted production at its Springfield plant on September 23, suspending production of GM-branded vehicles, as well as Navistar's own commercial trucks. On November 4, Navistar resumed production at its Springfield plant.

16:19 EST U.S. Steel commits to reduce greenhouse gas emissions intensity by 20% - United States Steel Corporation announced its plans to reduce greenhouse gas emissions intensity across its global footprint. The company has set a goal to reduce its global greenhouse gas emissions intensity by 20%, as measured by the rate of carbon dioxide equivalents emitted per ton of finished steel shipped, by 2030 based on 2018 baseline levels. This target will apply to U. S. Steel's global operations.

16:18 EST ascena retail appoints Justin MacFarlane Chief Customer Officer - ascena retail group announced that Justin MacFarlane has been appointed executive VP, Chief Customer Officer, effective December 2. MacFarlane most recently served as the Chief Strategy, Analytics and Innovation Officer at Macy's (M). In addition, Marisa Baldwin has been promoted to executive VP, Chief Human Resources Officer, effective immediately. Both MacFarlane and Baldwin will report directly to Gary Muto, CEO of ascena.

16:16 EST Matthews increases quarterly dividend by 5% - Matthews International Corporation announced that its board declared a dividend of 21c per share on the company's common stock, representing an increase of 5.0% to the company's dividend rate. The dividend is payable December 9 to stockholders of record November 25.

16:15 EST Turquoise Hill raises 2019 gold production guidance to 240K oz. from 230K oz. - Copper in concentrates remains in the 125,000-155,000 tons range. Continues to expect capital expenditures of $1.1B-$1.2B.

16:10 EST Cisco CEO says macro environment 'challenging' - "We delivered a solid quarter against a challenging macro environment," said Chuck Robbins, chairman and CEO of Cisco. "We're focused on continuing to drive innovation, transform our business and exceed our customers' expectations." "We performed well in Q1, growing revenue and delivering strong margins and EPS," said Kelly Kramer, CFO of Cisco. "With software subscriptions now at 71% of our software revenue, we are making good progress in transforming our business model. We continue to invest in our innovation pipeline to generate long-term profitable growth and deliver value for shareholders."

16:09 EST Cisco reports Q1 adjusted gross margin 65.9%

16:04 EST NetApp names James Whitemore CMO - NetApp announced the appointment of James Whitemore as senior vice president and chief marketing officer at NetApp, reporting to CEO George Kurian. Whitemore has been a key team member of the marketing organization since 2016 and served as interim CMO since July of 2019. "James has held the role of CMO across several organizations and understands where the market is going given his experience building cloud businesses," said Kurian. "He brings a strong balance of sales and marketing experience which is invaluable as the lines blur between the traditional sales motions and digital marketing. I'm excited to have him as part of the team as we continue to drive market leadership in cloud data services."

16:00 EST American Outdoor Brands trading halted, news pending

15:43 EST Qiagen shares surge as Thermo Fisher reportedly weighs purchase - Shares of Qiagen (QGEN) jumped in afternoon trading after Bloomberg reported that Thermo Fisher (TMO) is mulling an acquisition of the company and has approached it about a deal. Qiagen shares are up 7.8% after resume trading following a halt.

15:34 EST Qiagen trading halted, volatility trading pause

14:38 EST Disney confirms 10M sign-ups for Disney+ since yesterday's launch - Disney+, the streaming service from The Walt Disney Company, has "already reached a major milestone, achieving a remarkable 10 million sign-ups since launching," the company confirmed in a press release. Disney added: "Moving forward, there are no plans to release Disney+ subscriber data outside of The Walt Disney Company's quarterly earnings calls."

14:31 EST Lancaster Colony raises dividend to 70c from 65c per share - Lancaster Colony announced that its board of directors has declared a quarterly cash dividend of 70c per common share. The dividend will be payable December 31, 2019 to shareholders of record on December 6. CEO David Ciesinski said, "The increased regular cash dividend reflects the company's continued strong financial position and will be the 226th consecutive quarterly cash dividend paid by the company since September 1963." He noted that the indicated annual payout for the current fiscal year ending June 30, 2020 is $2.75 per share, up from the $2.55 per share paid in fiscal 2019.

14:20 EST Rockstar says 'Red Dead 2' PC stuttering due to issues with Nvidia drivers, GPUs - Take-Two's (TTWO) Rockstar games issued a statement on Twitter in response to complaints about the PC port of "Red Dead Redemption 2." "Over the past week, we have been working as quickly as possible to address issues that have impacted the launch of the PC version of Red Dead Redemption 2," the statement reads. "As a result we have already identified and resolved a number of these issues by deploying fixes to the Rockstar Games Launcher and some to the game itself. However, we are aware that a small number of Red Dead Redemption 2 PC players are still experiencing some ongoing problems with the game stuttering. We believe this is due to unforeseen issues related to specific combinations of Nvidia (NVDA) graphics drivers, Nvidia GPU cards and certain CPU's. We will be rolling out an update to the game today which will address the stuttering issue alongside a host of other fixes. However, we are still currently working together with Nvidia to completely resolve the stuttering issue in a future update, and it may take us up to a few days to properly test everything and ensure the next update completely solves the problem." Reference Link

13:52 EST Dropbox CEO Houston buys $9.57M worth of shares - Dropbox CEO Andrew Houston acquired 500,000 shares of the company at a price target of $19.14 per share, or $9.57M. Houston now directly owns over 10M shares of Dropbox and indirectly owns over 1.2M.

12:51 EST Chesapeake shares pop on asset sale talks as analyst comments on debt covenant - Shares of natural gas firm Chesapeake (CHK) are higher on Wednesday following a report that said Comstock Resources (CRK) is in talks to buy Chesapeake's Haynesville shale assets in Louisiana in a deal that could be worth more than $1B. COMSTOCK IN TALKS TO BUY CHESAPEAKE ASSETS: Comstock Resources is in talks to buy Chesapeake Energy's Haynesville shale assets in Louisiana in a deal that could be worth more than $1B, according to Reuters' Arathy Nair, citing sources. The two oil companies have settled on a structure for the deal and hope to finalize an agreement by year end, the report added. COVENANT BREACH HOPE: On Wednesday, Morgan Stanley analyst Devin McDermott downgraded Chesapeake to Equal Weight from Overweight with a price target of $1.25, down from $2.25, after the company issued a "going concern" warning that it may exceed certain debt covenants within the next 12 months. He estimates Chesapeake's leverage, excluding the "ring-fenced" Brazos Valley subsidiary, at 5.0 times on a rolling 12-month basis and while he expects the company to successfully manage through the potential covenant breach, it will likely require strategic action or waivers, said McDermott, who sees "a wide range" of potential outcomes. CHESAPEAKE CEO CONFIDENT: Chief Executive Officer Doug Lawler commented this week that "Chesapeake continues to strongly believe our current capital and operating program, coupled with the planned 30% reduction in capital expenditures in 2020, will strengthen the financial position of the company for the long term. We have substantial liquidity with no significant near-term maturities. We continue to pursue strategic levers to reduce debt, including asset sales, capital markets transactions, and focus on cost discipline. Additionally, we are de-risking our cash flows through our hedging program and remain confident in our long-term liquidity." PRICE ACTION: Shares of Chesapeake Energy are up over 7% to 73c in afternoon trading.

12:31 EST Disney rallies after announcing 10M streaming sign-ups - Shares of Walt Disney (DIS) moved higher after the company at midday announced that its Disney+ streaming service reached 10M sign-ups since yesterday's launch. Following the news, Disney is up 4% to $143.74 while streaming competitor Netflix (NFLX) dropped 1% to $288.16. Disney is offering a seven-day free trial, so likely not all of the sign-ups represent customers who will continue to pay for the service, CNBC points out. In addition, Verizon Communications (VZ) is also offering its customers a free year of Disney+, which could further boost the subscriber numbers.

12:08 EST Identiv partners with GTSC to address 'evolving threats' to U.S. agencies - Identiv announced that it has joined the Government Technology & Services Coalition, GTSC. By working with GTSC and its members, Identiv strengthens its commitment to delivering the quality products and services required to protect against, mitigate, and respond to security threats. Identiv delivers end-to-end solutions to the U.S. federal government, including its Hirsch Government Federal Identity, Credential, and Access Management, FICAM, Solution and Hirsch physical access control systems - featuring Hirsch Velocity Software, Hirsch ScramblePad Readers, and award-winning Hirsch Mx Controllers - IT-centric Freedom Access Control, and Thursby mobile security. The company's complete security platform has delivered the highest security and quality to U.S. federal government customers for almost 40 years. Identiv is the trusted provider of technologies to a wide range of government organizations, including the U.S Marshals Service, Department of Homeland Security, DHS, U.S. Treasury, Department of Defense, DoD, and Department of State.

12:04 EST Disney turns positive after announcing 10M streaming sign-ups - The stock is up 15c to $138.73 after being down earlier in the morning.

12:00 EST Energizer rises 13.2% - Energizer is up 13.2%, or $5.54 to $47.54.

12:00 EST Line Corp. rises 21.9% - Line Corp. is up 21.9%, or $8.92 to $49.70.

11:14 EST Instructure up 3% as company said to be exploring sale - Shares of Instructure are up 3% to $49.39 after Bloomberg's Kiel Porter, Scott Deveau and Gillian Tan reported that the company is exploring a sale and a number of private equity firms are weighing bids. Reuters reported on October 31 that activist Sachem Head Capital Management had established a new stake in Instructure and intended to push the company to explore alternatives and Bloomberg previously said on November 6 that activist Praesidium was also calling for Instructure to pursue a sale.

10:32 EST Manulife Financial, TTC resolve matter related to Healthy Fit case - Manulife and the Toronto Transit Commission have resolved the matter related to the Healthy Fit case. Terms of the settlement, which is related to a 2016 TTC statement of claim, were not disclosed. The parties said,"Manulife and the TTC remain united in a commitment to fraud prevention and collaborated on the investigation that brought Healthy Fit to justice. We're pleased to have worked together, with law enforcement, to stop a fraudulent provider. Healthy Fit owner, Adam Smith, was convicted and sentenced in 2017. "

10:21 EST Netflix, Nickelodeon to produce original animated feature films and TV series - Netflix (NFLX) and Nickelodeon announced that they have formed a new, multi-year output deal to produce original animated feature films and television series based both on the Nickelodeon library of characters as well as all-new intellectual property. "This marks an expansion of the existing relationship between the companies, which has already brought several popular titles to Netflix, including animated specials Rocko's Modern Life: Static Cling and Invader Zim: Enter the Florpus. Also forthcoming are specials based on The Loud House and Rise of the Teenage Mutant Ninja Turtles," the companies said in a statement. Nickelodeon and all related titles, characters and logos are trademarks of Viacom (VIA,VIAB). Reference Link

09:58 EST Hawaiian Electric board says ValueAct letter seeking new CEO 'disappointing' - Jeff Watanabe, Chair of Hawaiian Electric's board, said in a letter to shareholders, "This week, Jeff Ubben, founder of the ValueAct Spring Fund, published a letter to the community of Hawaii. Frankly, the letter is disappointing. While Jeff Ubben is entitled to his own opinion, he is not entitled to his own facts. The letter is a misguided, factually inaccurate and misleading attack on HEI, Hawaiian Electric and our commitment to renewable energy, the state of Hawaii and our valued customers and investors. The ValueAct Spring Fund has been a shareholder of HEI for just over a year and is new to getting to know Hawaii and the community our company has served for 128 years. ValueAct has raised the issues in their letter in the past, and we've addressed those directly with Mr. Ubben and his ValueAct colleagues. They don't seem interested in the facts but rather seem intent on pursuing their own agenda - specifically, handpicking a CEO for HEI...We have a strong, capable, independent Board of Directors that takes succession planning seriously and has robust, timely and appropriate succession planning processes in place. The Board has recently added new directors (including one suggested by ValueAct) as part of our ongoing board refreshment process and to maintain the diversity of experience and expertise necessary to oversee the company's strategic direction, including our move to a renewable and sustainable future."

09:55 EST Occidental sees proceeds from asset sales of at least $15B by middle of 2020

09:47 EST SandRidge Energy falls -7.5% - SandRidge Energy is down -7.5%, or -35c to $4.29.

09:47 EST Spectrum Brands rises 9.1% - Spectrum Brands is up 9.1%, or $4.69 to $55.95.

09:47 EST Energizer rises 15.4% - Energizer is up 15.4%, or $6.45 to $48.45.

09:39 EST Cintas down 3% to $251.45 after Spruce Point issues short report

09:19 EST Neoleukin Therapeutics expects cash to fund operations through 2021 - Cash and cash equivalents totaled $66.3 million as of September 30, 2019, compared to $76.9 million as of December 31, 2018. The decrease was primarily the result of expenses related to the merger, the cost of expanding the Neoleukin team, and NL-201 IND-enabling activities. Neoleukin expects its cash and cash equivalents to be sufficient to support the development of internal programs. Based upon current internal infrastructure and pipeline initiatives, Neoleukin believes that its cash-on-hand will be sufficient to fund operations through 2021.

09:15 EST Avid Technology provides audio solutions to SiriusXM 's Jazz at Lincoln Center - Avid (AVID) announced that long-time customer SiriusXM Satellite Radio (SIRI) has upgraded its Jazz at Lincoln Center mixing and recording studios with Avid audio hardware and software solutions for its popular live music broadcasts on radio and online streaming. The satellite radio broadcasting company has upgraded its workflow with Pro Tools HDX systems, Avid S6 control surfaces, and Pro Tools MTRX audio interfaces. The upgrade gives Rob Macomber, SiriusXM's chief engineer of the studios at JALC, the sound quality, reliability and flexibility he needs to mix, record and produce the JALC broadcasts.

09:14 EST LastPass, HP collaborate to boost online security - LogMeIn (LOGM) announced HP (HPQ) will offer easy access to its password management solution, LastPass, to select customers who purchase the new HP Spectre x360 13. Accessible via a Windows Start Tile, HP customers can create a free LastPass account for a simple, secure way to manage passwords and other confidential information. With LastPass, users can store everything from bank accounts to passports to credit card numbers securely in their personal vault, where such information can be organized into folders, shared with others, and given to a family member in the event of an emergency. The LastPass Personal suite includes LastPass Free and Premium for individuals and Families which includes 6 licenses.

09:11 EST MTBC announces signing of orthopedic practice in New Jersey - MTBC announced that one of New Jersey's leading orthopedic practices has selected MTBC's end-to-end revenue cycle management and request of information solutions, capping one of MTBC's strongest years of new signings. The most recently signed practice, which specializes in orthopedic surgery, sports medicine, and therapeutic services, employs more than 30 providers at its 9 locations.

09:08 EST Sanuwave Health signs distribution partnership with Ametus Group - SANUWAVE Health announced that it has signed a distribution partnership agreement with Ametus Group for the commercialization of the dermaPACE System for the treatment of diabetic foot ulcers in the United States. Leveraging Ametus Group's fifty dedicated wound care sales force allows SANUWAVE to ramp up placements much faster than previously expected in a cost effective and capital efficient manner.

09:06 EST Caterpillar reports retail machines sales up 3% in three months end October - Caterpillar reported in a regulatory filing that its total retail machines sales were up 3% on a three month rolling basis in October. For reference, retail sales of machines were up 6% in the period ending in September and up 4% in the period ending in August. The company reported World Resources Industries sales were up 7% in the October-end period, compared to a September-end period increase of 14% and an August-end period increase of 25%. Construction Industries world sales were up 2% in the October-end period, versus up 4% in the prior three-month period ending in September. Total Energy & Transportation Retail Sales were down 4% in the October-end period, and were up 6% in the September-end period.

09:04 EST iHeartMedia, Varo Money announce marketing partnership - Mobile banking company Varo Money announced a multimillion dollar marketing partnership with iHeartMedia. Under the agreement, Varo will launch an extensive three-year campaign across iHeartMedia's multi-platform audio network, including its broadcast radio, digital, podcast, social, and live events platforms. The deal helps build further awareness of Varo as one of the most-loved challenger banking companies in the United States and will kick off with a seven-week campaign that spans the largest radio metros in the country, including radio talent out of Atlanta, Chicago, Houston, Dallas, Miami, San Francisco, Phoenix, Las Vegas, Los Angeles, and New York. The multi-year deal with iHeartMedia, which has more than 850 radio stations and reaches a quarter of a billion consumers every month through its broadcast radio assets alone, adds momentum to Varo's hyper-growth around the country.

09:03 EST Yext, Nextdoor announce global integration - Yext and Nextdoor announced a global integration allowing businesses using Yext to publish facts about them to their Nextdoor Business Pages. The integration gives businesses confidence that consumers searching for them on Nextdoor will get an accurate, brand verified answer. With this new relationship, people in the neighborhood can find facts like business locations, contact information, hours of operation, and more, straight from the business itself on their Nextdoor Business Page.

08:59 EST Fly Intel: Pre-market Movers - HIGHER: Tech Data (TECD), up 3% after announcing it will be acquired by an affiliate of funds managed by Apollo Global (APO) for $130 per share in a transaction with an enterprise value of approximately $5.4B. UP AFTER EARNINGS: Spectrum Brands (SPB), up 7%...Datadog (DDOG), up 14%... Fiverr (FVRR), up 7%... 2U (TWOU), up 12%... Luckin Coffee (LK), up 14%... Cardlytics (CDLX), up 18%. DOWN AFTER EARNINGS: SmileDirectClub (SDC), down 8%... Stratasys (SSYS), down 5%... Meritor (MTOR), down 10%... Tilray (TLRY), down 2%... Skyworks (SWKS), down 5%... Cheetah Mobile (CMCM), down 2%. ALSO LOWER: Alcoa (AA), down 2% after BofA Merrill Lynch analyst Timna Tanners downgraded shares to Underperform from Neutral with a $21 price target. The analyst cites limited catalysts and a cautious aluminum view, adding that while the stock price has risen about 16% since reporting Q3, aluminum price was up only about 6% in that time frame.

08:48 EST Walmart Canada selects Telus Health pharmacy management solution - Walmart Canada (WMT) announced that it has selected TELUS Health's (TU) next generation pharmacy management solution, Ubik, for all of its Acces pharma franchised locations across the province of Quebec. The province-wide rollout is modernizing 68 locations so patients in Quebec can access more clinical health services while pharmacists streamline operations management and collaborate digitally with other healthcare professionals within a connected healthcare ecosystem.

08:46 EST Aquestive Therapeutics licenses riluzole oral film to Zambon - Aquestive Therapeutics announced that it granted a license to Zambon S.p.A. for the development and commercialization of Riluzole Oral Film in the European Union for the treatment of amyotrophic lateral sclerosis. ROF, utilizing Aquestive's proprietary PharmFilm technology, is being developed for the treatment of ALS, a debilitating disease affecting as many as 30,000 Americans and 52,000 Europeans. Once approved, ROF may potentially fulfill a critical need for ALS patients, given it can be administered safely and easily, twice daily, without water. Development initiatives conducted by Aquestive have included studies demonstrating ROF's pharmacokinetic bioequivalence to the reference listed drug, Rilutek, as well as additional studies to assess patients' ability to swallow ROF. The product is currently under review by the U.S. Food and Drug Administration for marketing approval in the United States and has an anticipated PDUFA date of November 30, 2019. ROF received FDA orphan drug designation in January 2018. Under the terms of the license agreement, Zambon will pay to Aquestive an undisclosed upfront payment for the development and commercialization rights for ROF in the EU, along with additional development and sales milestone payments and low double digit royalties on net sales of the product in the EU. Zambon will be responsible for the regulatory approval and marketing of ROF in the EU and Aquestive will be responsible for the development and manufacturing of the product.

08:36 EST Soleno Therapeutics expects topline data for Phase III DESTINY PWS study in 1H20

08:34 EST Allegheny Technologies, NLMK renew carbon steel hot-rolling conversion agreement - Allegheny Technologies announced it signed another one year agreement to extend and expand carbon steel hot-rolling conversion services for NLMK at its hot-rolling and processing facility, or HRPF, located in Brackenridge, PA. The continuation of this relationship is an important element of ATI's drive to achieve improved and sustainable profitability in its flat rolled products segment. ATI expects 2020 volumes covered under this agreement to meaningfully increase over 2019 levels. This agreement includes significant guaranteed volumes and fixed fee-per-ton revenues. It provides NLMK USA with continued access to the HRPF's capabilities for conversion of their broad range of carbon steel grades through December 2020.

08:30 EST ChaSerg Technology Acquisition Corporation (Class A Stock) trading resumes

08:22 EST Alico announces expected dissolution of largest shareholder 734 Investors - Alico announced that 734 Investors, the Company's largest shareholder, has distributed the 3,173,405 shares of Company common stock held by it, on a pro rata basis, to its members. This share distribution comes in anticipation of the dissolution of 734 Investors later this year. Transfers of these shares are not registered on any current Alico registration statement, but the shares are potentially transferable pursuant to Rule 144, subject to certain customary restriction.

08:17 EST ManTech awarded $82M NSWC Crane task order to support unmanned ISR aircraft - ManTech announced that it has been awarded a five-year $82M prime task order to provide analysis, research and development support for the U.S. Naval Surface Warfare Center Crane Division in support of Naval Air Systems Command unmanned aircraft. ManTech was awarded this contract under the Department of Defense Information Analysis Center'sMultiple Award Contract that allows for competition at the task order level. These DoD IAC MAC task orders are awarded by the U.S. Air Force Installation Contracting Center to ManTech for work to be performed for various U.S. military organizations. The cost-plus-fixed-fee task order was awarded under the DoD IAC MAC, Pool 1. ManTech won a seat on the IAC MAC contract in 2018. Under this new task order, ManTech will support DoD IAC's mission by enabling collection, analysis, synthesizing/processing, and dissemination of Scientific and Technical Information in the areas of analysis, research and technology development to advance sophisticated capabilities of MQ-4C Triton systems. Comparable work may include support for the U.S. Navy's MQ-8 Fire Scout autonomous helicopter, the MQ-25 Stingray aerial refueling drone, and U.S. Air Force unmanned platforms. This will assist a variety of USAF and DoD customers to discover hidden correlations, better understand data analysis results, and make more informed decisions. The work will be performed primarily at ManTech's facility in Crane, Indiana.

08:13 EST Alimera Sciences terminates equity purchase agreement - Alimera Sciences announces that it has terminated its $20M common stock purchase agreement with Lincoln Park Capital Fund, effective November 12, 2019. "After assessing our expectations for the remainder of this year and plans for 2020, we have made the decision to terminate our equity purchase agreement. Having completed the third quarter of 2019 at an annualized revenue run rate in excess of $50 million, we believe we have sufficient cash on hand to fund our operations throughout 2020," said Rick Eiswirth, president and CEO of Alimera. "Currently we believe that our common stock is significantly undervalued and we have no plans to issue equity at these levels. We continue to expand the usage of ILUVIEN both domestically and internationally and believe the best course of action is to continue to execute this plan without further dilution to our stockholders at this time. We appreciate the commitment from LPC and their initial investment of $1.0 million." Other than the initial investment, Alimera has not requested any additional purchases under the agreement.

08:09 EST Allena expects to file investigational NDA with FDA for ALLN-346 this quarter - ALLN-346 is an orally administered, novel urate degrading enzyme that has been designed for activity and stability in the gastrointestinal tract. Allena is completing its preclinical development of ALLN-346 for the treatment of hyperuricemia in patients with gout in the setting of advanced CKD and also scaling its manufacturing processes to support clinical studies. Allena expects to file an Investigational New Drug application with the U.S. FDA this quarter and to initiate the first clinical trial of ALLN-346 in the first half of 2020.

08:08 EST Allena Pharmaceuticals expects URIROX-2 data in 2H21 - Allena continues to evaluate the full data from URIROX-1 and will assess the implications for URIROX-2, its second, larger pivotal Phase 3 trial, including the adaptive design elements of URIROX-2. URIROX-2 is ongoing, with topline data expected in the second half of 2021. Allena plans to file a Biologics License Application with the FDA for reloxaliase using the accelerated approval regulatory pathway based on the URIROX-1 results and 24-week biomarker data from the ongoing URIROX-2 trial, pending positive results. Patients will continue on therapy in URIROX-2 to confirm clinical benefit during the long-term follow-up phase of the trial.

08:05 EST Eastside Distilling names Lawrence Firestone as new CEO - Eastside Distilling announced the appointment of Lawrence Firestone as the company's new CEO. Firestone has over 35 years of enterprise, operations and financial management experience in both public and private companies, with tenures as CEO, CFO and COO across multiple industry sectors. Firestone most recently served as Executive Vice President and CFO of Akonni Biosystems, a privately-held developer of molecular diagnostic platforms.

08:04 EST Luokung Technology acquires 51% of EMG from Geely, Acuitas Capital - Luokung Technology announced that Geely Technology Group Co. and Acuitas Capital have made strategic investments in Luokung Technoloy Corp. through the purchase of preferred shares and common stock. The investment of $42.5M from Geely prompt the company to complete the acquisition of 51% of eMapgo Technologies Co., Ltd. As a result, the company will immediately begin to consolidate the financial results of EMG, which will be reflected in the company fourth quarter and year-end financial results. The company anticipates receiving funding of up to $100M from Acuitas to acquire the remaining equity of EMG. Thus, the company expects to acquire the balance of EMG by the end of the year. Since the Company made announcement on August 28, 2019, the company has begun to pay EMGs' shareholders in installments based on the acquisition agreement and the supplementary agreement. At the current stage, through cash payment and the payment of common stock and preferred stock, the company shall obtain more than 51% of EMG's shares, and the company expects to complete the 100% of the Acquisition of EMG before December 31.

08:03 EST NextGen Healthcare to acquire Medfusion for $43M in cash - NextGen Healthcare announced an agreement to acquire Medfusion. The proposed acquisition is expected to close in early December, subject to the satisfaction of closing conditions, including the transfer of Medfusion's data services business out of Medfusion. The total purchase price of $43M, subject to customary adjustments, will be paid in cash at acquisition completion.

08:00 EST Acasti Pharma says on track to report results fror TRILOGY 1 in December

07:59 EST Acasti says uncertainty exists about ability to continue as going concern

07:47 EST Abbott says Robert Ford to succeed Miles White as CEO on March 31, 2020 - Abbott announced that Miles White will be stepping down as CEO on March 31, 2020, after a remarkable 21-year tenure, the second longest for a non-founder in today's S&P 100. He will remain Executive Chairman of the Board. The Board has unanimously appointed Robert Ford, a 23-year Abbott veteran, to succeed White as CEO. Ford currently serves as President and COO and has been elected to the Board. Ford will become the 13th CEO of Abbott in its 131-year history, all having been appointed from within the company, a testament to Abbott's strong management philosophy and succession-planning discipline. Ford originally joined Abbott in the company's Diabetes Care business in 1996. He was appointed President and COO in October 2018.

07:45 EST Abbott says Robert Ford to succeed Miles White as CEO on March 31

07:38 EST KalVista now expects to complete enrollment for KVD900 Phase 2 trial in 2019 - KalVista provided an update on the status of its development programs. KalVista now expects to complete enrollment for the KVD900 Phase 2 clinical trial before year-end 2019 and to provide data in 2020. The Phase 2 clinical trial of KVD001 in DME is still expected to provide data this quarter. "We are pleased with the rate of enrollment of our Phase 2 clinical trial of KVD900 in HAE patients," said Andrew Crockett, CEO of KalVista. "Our plan to recruit patients primarily in European HAE centers is serving us well, with good recruitment at our clinical sites. Regulatory and ethical approvals have been timely, although start-up at several sites has taken longer than anticipated. We have identified a robust pipeline of patients eager to try a potentially efficacious oral on-demand treatment, and we anticipate that we will complete recruitment before year-end 2019 and provide data in 2020."

07:28 EST Recro Pharma announces effectiveness of Baudax Bio Registration Statement - Recro Pharma announced that the U.S. Securities and Exchange Commission has declared effective the Registration Statement on Form 10 filed by Baudax Bio Inc. Recro expects to complete the separation of Baudax Bio into an independent, publicly traded pharmaceutical company focused on advancing promising, non-opioid analgesics and other products for acute care settings on November 21, 2019. Recro's board of directors approved the planned separation of Recro and Baudax Bio on November 5, 2019, and declared a special dividend distribution of one share of Baudax Bio common stock for every two and one half shares of Recro common stock held as of the close of business on November 15, 2019, the record date for the distribution. Shareholders will receive cash in lieu of fractional shares. The special dividend distribution is expected to be paid on November 21, 2019. There is no current market for Baudax Bio common stock. NASDAQ has approved the listing of Baudax Bio common stock on the NASDAQ Capital Market under the symbol "BXRX." NASDAQ has advised that Baudax Bio common stock will begin trading on a "when-issued" basis under the symbol "BXRXV" on November 14, 2019. Additionally, Recro expects that starting on November 14, 2019, common stock of Recro will trade on the NASDAQ Capital Market in two markets: "regular-way" under the symbol "REPH" and in the "ex-distribution" market under the symbol "REPHV." Shares of Recro common stock trading under "REPH" will carry the right to receive shares of Baudax Bio common stock, if held as of the close of business on November 15, 2019. Shares of Recro common stock trading under "REPHV" will not carry the right to receive shares of Baudax Bio as part of the special dividend distribution. If shares of Recro common stock are sold in the "regular-way" market after November 15, 2019 but before the distribution date, the shareholder is selling the right to receive shares of Baudax Bio common stock with respect to such Recro shares as part of the distribution. Recro shareholders are encouraged to consult with their financial advisors regarding the specific consequences of selling Recro common stock on or before that date. Following the distribution, regular-way trading will commence on NASDAQ for Baudax Bio under the symbol "BXRX" and will continue for Recro under the symbol "REPH." Following the separation, Baudax Bio will be an independent, publicly traded pharmaceutical company focused on advancing promising, non-opioid analgesics and other products for acute care settings.

07:24 EST Whitestone REIT completes redevelopment investment at Williams Trace Plaza - Whitestone REIT announced the completion of its Williams Trace Plaza Redevelopment Investment. The project, designed to upgrade ADA accessibility at the property and to improve the shopping experience for all of our customers, included renovation work on the center. Enhancements added through the Redevelopment Investment include: Enhanced Walkability and Access for all Shoppers; Expansion of Outdoor Seating and Gathering Areas; "Greening of Space" Through the Addition of Native Plants and Shrubs as part of the Landscaping Improvement; "Harvesting of Natural Light" in both the Interior and Exterior Designs; Installation of LED Lighting for Energy Conservation and Upgraded Irrigation and Drainage Systems for better Natural Water Flood Management. Whitestone originally acquired Williams Trace Plaza in December of 2014 for $20.1M and subsequent to acquisition has invested an additional $2.1M in enhancements to the property. The property is currently 93% occupied and produces annual net operating income of approximately $1.7M.

07:17 EST Sol-Gel Technologies expects results from bioequivalence study in 2019 - Results from a bioequivalence study for generic 5-fluorouracil cream, 5%, for actinic keratosis, continue to be expected by the end of the year followed by a filing in the U.S. of an abbreviated New Drug Application expected in 2020. This study is part of a collaboration with Douglas Pharmaceuticals.

07:16 EST Sol-Gel expects top-line results from Phase 3 trials of Twyneo in Q4 - Top-line results of the two pivotal Phase 3 trials evaluating Twyneo cream in acne vulgaris continue to be expected in the fourth quarter of 2019.

07:13 EST Liquidia Technologies aims to initiate LIQ865 Phase 2 program in 2020 - Phase 2-enabling toxicology studies were initiated earlier in 2019 to assess LIQ865 in multiple non-clinical tissue models. Results from a study to assess incision tensile strength after healing were acceptable and not statistically different from controls. In a study to assess bone fracture healing, the Company observed dose-dependent delayed healing at the two LIQ865 doses studied; however, there were no adverse effects noted on surrounding soft tissues. Additional studies are planned with lower doses of LIQ865 to determine a no adverse effect level on bone healing. Results from an additional soft tissue toxicology study are expected later in the fourth quarter of 2019. Results from these toxicology studies will be reviewed in 2020, and provided the data are supportive, the Company intends to initiate a Phase 2 program.

07:11 EST Liquidia Technologies expects to submit NDA for LIQ861 in 1Q20 - The registrational studies for LIQ861 have been completed and the Company is proceeding with plans to submit the NDA for the treatment of adults with pulmonary arterial hypertension. Final enrollment in the pivotal INSPIRE trial included 121 PAH patients to assess safety and tolerability through Month 2, the primary endpoint of the trial. Consistent with preliminary data presented in the second quarter of 2019, LIQ861 was observed to be well-tolerated and treatment-emergent adverse events were mostly mild to moderate in nature. In addition to INSPIRE, a second supplemental pharmacokinetics study was completed, the results of which the Company believes further confirm the comparative bioavailability of 75 mcg capsule strength LIQ861 to 54mcg of Tyvaso, the reference listed drug.

07:07 EST AcelRx reports efficacy data on sufentanil tablets - AcelRx announced a publication analyzing pooled dosing and efficacy data from use of the sufentanil sublingual tablet 30 mcg among multiple demographic subgroups. This data, published in the Journal of PeriAnesthesia Nursing, was analyzed to aid nurses in understanding the effectiveness and duration of action of SST 30 mcg in the management of moderate-to-severe acute pain across a variety of patient demographics. Mean drug doses administered from 0-12 hours was 3.9 for SST 30 mcg, and was less frequent for older than 65 years vs. younger patients but was similar among other subgroups. Summed pain intensity difference to baseline over 12 hours was higher in the SST 30-mcg group compared with placebo across all demographic subgroups. "We are pleased with the results of this analysis, particularly that a single dosage-strength tablet has efficacy across all the demographic subgroups," commented CMO Pamela Palmer. "An important reason behind the development of Dsuvia was to avoid common opioid medication errors occurring with the clear injectable opioids, which come in widely differing concentrations2.

07:04 EST Zomedica adds veterinary clinic to ZM-006 pilot efficacy study - Zomedica has widened its pilot efficacy study of ZM-006, initiated in partnership with University of Georgia's veterinary teaching hospital, to include Quakertown Veterinary Clinic, an American Animal Hospital Association accredited, high-traffic referral clinic in Pennsylvania with 37 veterinarians, of which 24 specialize in small animal health. Methimazole in oral form is used for the medical management of hyperthyroidism in cats and is the standard of care for the treatment of over-active thyroid in cats. Zomedica's ZM-006 is a transdermal gel designed to be a single daily dose applied to a cat's ear which is intended to be less stressful for both owners and their feline companions. The pilot efficacy study commenced in March and is expected to be completed by the end of the year.

06:57 EST Canada Goose up 7.5% to $42.00 after Q2 results, FY20 guidance

06:49 EST Canada Goose reiterates fiscal 2020 outlook issued on May 29 - On May 29 the company guided FY20 adjusted EPS growth at least 25% and FY20 revenue growth at least 20%. Targeted wholesale revenue growth in the high-single-digits on a percentage basis, eight new retail stores in operation by the end of the winter selling season, one new digital concept store in operation by the end of the winter selling season.

06:34 EST Autolus Therapeutics, Noile-Immune announce licensing agreement - Autolus Therapeutics and Noile-Immune Biotech announced that they have entered into a license agreement whereby Autolus will have the right to develop CAR T cell therapies incorporating Noile-Immune's PRIME technology secreting both IL-7 and CCL19. The PRIME technology is designed to improve proliferation and trafficking into solid tumors of both engineered CAR T cells as well as the patient's own T cells. Through the license agreement with Noile-Immune, Autolus has gained the right to incorporate the PRIME technology in its CAR T cell programs against a limited number of cancer targets. Autolus will make an upfront cash payment and milestone payments to Noile-Immune, and Noile-Immune is also entitled to receive royalties on net sales of resulting products. Additional terms of the agreement were not disclosed.

06:31 EST Spectrum Brands says expects to repurchase additional $250M of common stock - "We ended the year strong, with Q4 organic sales growth of more than 3%, adjusted EBITDA growth of more than 5%, a significantly improved balance sheet and delivery of full-year results within our guidance," said David Maura, Chairman and CEO of Spectrum Brands Holdings. "We believe our actions this year reflect decisions that will drive long-term value creation and sustainable growth. Our accomplishments included materially reducing net debt, closing on the divestitures of two business units and returning over $350 million to our shareholders. We further plan to repurchase up to $250 million of our shares through a $125 million Accelerated Share Repurchase program beginning next week, and additional open market repurchases. This reflects our Board's confidence in the long-term value of Spectrum Brands and its growth prospects. We have and will continue to drive vision, clarity and focus across our business units as we build a true ownership-mentality culture. Looking ahead, we plan to grow organic sales, EBITDA and adjusted free cash flow in 2020 and beyond," said Maura.

06:06 EST Lilis Energy names Joseph Daches as CEO - Lilis Energy announced that Joseph Daches has been appointed CEO. Daches, who joined Lilis Energy in 2016, has over 25 years of experience and expertise in directing strategy and finance in primarily small and mid-size oil and gas companies. Daches has helped guide several oil and gas companies through financial strategy activities, capital raises, and both public and private offerings

06:01 EST Tech Data to be acquired by Apollo Global for $130 per share in cash, or $5.4B

05:26 EST Marker Therapeutics says FDA placed clinical hold on leukemia trial - The company said in last night's earnings release, "We recently filed an Investigational New Drug application with the U.S. Food and Drug Administration for our MultiTAA T-cell therapy as part of a planned Marker Phase 2 study in post-allogeneic hematopoietic stem cell transplant patients with acute myeloid leukemia in both the adjuvant and active disease setting. The FDA reviewed our submission and requested additional information regarding certain quality and technical specifications for two reagents supplied by third party vendors that are used in our manufacturing process. Because the FDA requires these data in order to clear the IND, the Marker AML trial has been placed on clinical hold until our complete response to the technical questions is satisfactory to the FDA. While these reagents are not present in the final product, we worked with respective manufacturers of these reagents to satisfy the FDA's questions and subsequently submitted a complete response to the FDA in late October. We currently project to initiate our Phase 2 trial in 2020 and look forward to providing an update on our clinical path forward upon receiving the FDA's feedback." Marker added that it worked with regulatory and quality groups at the respective manufacturers to address the FDA's request and submitted a complete response to the issues raised by the FDA on October 28. The FDA will respond within 30 days after receiving Marker's complete response, indicating whether the hold is lifted and, if not, specifying the reasons the clinical trial remains on hold, the company said. Marker expects to initiate its Phase 2 clinical trial of MultiTAA therapy for the treatment of post-transplant AML in 2020.

05:24 EST Best Inc announces $100M share repurchase program - Best Inc announced that the board of the company has authorized a share repurchase program whereby BEST may repurchase up to $100M worth of its outstanding ADSs from time to time during the next 18 months.

05:10 EST Centogene signs data access and collaboration agreement with Pfizer - Centogene (CNTG) announced a new data access and collaboration agreement with Pfizer (PFE). The agreement grants Pfizer access to Centogene's data repository, which may be used in the discovery and validation of novel genetic and biochemical targets for the potential development of new therapies for rare diseases. Under the terms of the agreement, Centogene and Pfizer will work together to mine the data repository and jointly agree to any collaborative research projects designed to substantiate results of data mining. Centogene will receive an upfront payment and will be eligible for additional research payments under any future collaborative research projects. Individual-level data from the repository will be managed, protected and shared with Pfizer in compliance with international data privacy regulations.